The stock of Teladoc Health, Inc. (NYSE:TDOC) is now priced at $208.57 and the shares are -7.2 points down or -3.34% lower compared to its previous closing price of $215.77. The stock had 3.296 million contracts set over the past session. TDOC shares’ daily volume is compared to its average trading volume at 3.662 million shares. However, it has a float of 80.33 million and although its performance was -6.64% over the week, it’s one to watch. Analysts have given the TDOC stock a yearly average price target of $229.08 per share. It means the stock’s upside potential is 9.83% with the TDOC share price recently placing at $207.36 to $218.2. However, some brokerage firms have priced the stock below the average, including one that has called $157.
The shorts are running away from the Teladoc Health, Inc. stock, with the latest data on short interest released on July 31, 2020, showing that short interest numbers in the TDOC shares have declined. Short interest in the stock represents just 15.29% of its float, but the volume has dropped by 0.
In the last trading session, Teladoc Health, Inc. (NYSE:TDOC) dropped by -$14.84 over the week and lost -$29.06 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $253. The stock recorded its established 52-week high on 08/04/20.
Since 09/03/19, the stock has traded to a low of $55.94 at 282.13%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 0.31. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.
Looking at current readings, Teladoc Health, Inc.’s two-week RSI is 49.43. This suggests that the stock is neutral at the moment and that TDOC shares’ price movement remains stable. The stochastic readings are equally revealing at 59.94% meaning the TDOC share price is currently in neutral territory.
The technical chart shows that the TDOC stock will likely settle at between $215.39 and $222.22 per share. However, if the stock dips below $204.55, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $200.54.
Currently, the stock is trading in the red of MACD, with a reading of -2.27. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.
Analysts at Credit Suisse raised their recommendation for TDOC from Neutral to Outperform in August 17 review while maintain their target price of $225 to $249. Citigroup analysts see the stock as a Buy with a target price of $275 in a flash note released to investors on July 14 initiating covering the stock. Argus analysts see the stock as Buy when the analysts initiated the share price coverage on July 13, placing it at $280.
The average rating for the TDOC equity is 2.23 and is currently gathering a bullish momentum. Of 26 analysts tracking Teladoc Health, Inc. polled by Reuters, 10 rated TDOC as a hold. The remaining 16 analysts were split evenly. However, the split wasn’t equal as a majority (16) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.
Zacks Consensus Estimate forecasts that the current-quarter revenues for Teladoc Health, Inc. (NYSE:TDOC) will decrease by about -99.88%, which will see them reach $282 million. The company’s full-year revenues are, however, expected to increase by about 79.07%, up from $553 million to $991 million. TDOC’s expected adjusted earnings should surge almost 14.29% to end up at -$0.32 per share, while for the fiscal year, analysts project the company’s earnings to grow by about 1.45% to record -$1.4/share.